Blockchain Registration Transaction Record

Glioblastoma's Grim Reality: 75% Don't Reach 2-Year Remission

Glioblastoma has only 25% 2-year remission rate. Learn about CNS Pharmaceuticals' research and current treatment challenges for this deadly brain cancer affecting thousands annually.

This news matters because glioblastoma affects approximately 12,000 Americans annually with devastating consequences for patients and families. The extremely low remission rates highlight a critical gap in cancer treatment that impacts healthcare systems, research priorities, and patient outcomes. For the general public, understanding these statistics provides context for why brain cancer research funding and clinical trial participation are so vital. The involvement of companies like CNS Pharmaceuticals demonstrates the ongoing pharmaceutical industry efforts to develop better treatments, which could eventually lead to improved survival rates and quality of life for patients facing this currently incurable disease.